InMed Pharmaceuticals Inc. 8K

Mentari Therapeutics announced a $200 million private placement to fund its migraine prevention pipeline and extend its cash runway, to close in connection with its planned merger with InMed Pharmaceuticals and a concurrent $290 million financing.

On July 22, 2026, Mentari Therapeutics, Inc., a privately held biotechnology company focused on migraine prevention, announced a $200 million private placement of common stock and pre-funded warrants to leading healthcare investors, with proceeds expected to extend its cash runway into 2029, fund Phase 2a readouts for its two PACAP-targeted lead programs including MT-002, and support its broader migraine prevention pipeline; the financing is expected to close immediately prior to the completion of Mentari’s merger with InMed Pharmaceuticals, Inc. and concurrently with a previously announced $290 million private placement, after which the combined company will operate under the Mentari Therapeutics name, trade on the Nasdaq Capital Market under a new ticker symbol, and have an estimated 601,195,812 shares of common stock outstanding on an as-converted/as-exercised basis.

Filing Facts

CIK

1728328

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-080414

Alert Tier

8